These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 30238326)

  • 21. Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.
    Hajder M; Hajder E; Dervisefendic M; Samardzic R; Alic E
    Med Arch; 2013; 67(3):181-4. PubMed ID: 23848038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
    Delgrange E; Daems T; Verhelst J; Abs R; Maiter D
    Eur J Endocrinol; 2009 May; 160(5):747-52. PubMed ID: 19223454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
    Grebe SK; Delahunt JW; Feek CM
    N Z Med J; 1992 Apr; 105(931):129-31. PubMed ID: 1560924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
    Kim D; Ku CR; Kim K; Jung H; Lee EJ
    Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
    Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
    Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Giant prolactinomas in women.
    Delgrange E; Raverot G; Bex M; Burman P; Decoudier B; Devuyst F; Feldt-Rasmussen U; Andersen M; Maiter D
    Eur J Endocrinol; 2014 Jan; 170(1):31-8. PubMed ID: 24088550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
    Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
    J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
    Huang HY; Lin SJ; Zhao WG; Wu ZB
    Metab Brain Dis; 2018 Jun; 33(3):969-976. PubMed ID: 29546691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
    Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
    Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
    Kontbay T; Şıklar Z; Özsu E; Uyanık R; Bilici E; Ceran A; Berberoğlu M
    Turk J Pediatr; 2022; 64(5):892-899. PubMed ID: 36305439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
    Tirosh A; Benbassat C; Shimon I
    Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
    Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
    Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
    Casulari LA; de Castro LF; Kessler IM; Mendonça JL; de Fátima Magalhães Gonzaga M
    J Med Case Rep; 2019 Jun; 13(1):183. PubMed ID: 31202268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.
    Araújo C; Marques O; Almeida R; Santos MJ
    Endocrine; 2018 Nov; 62(2):470-476. PubMed ID: 30088141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
    Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.